

## OVERVIEW – Monday, 21 September 2009

Room	Plenary	Harvard	Stanford	Princeton	Foyer
Time					
09.15 – 10.15	Opening Ceremony				Registration 08.00 – 18.00
10.15 – 11.00	PL-01 Gene-environment interaction				
11.00 – 11.30	Coffee Break				
11.30 – 13.00	S-01 What can we learn from genetic research for the treatment of schizophrenia?	S-02 From stigma research to mental health policy	S-03 Prevention of psychosis – current state and evolving strategies	S-04 Treatment of first episode psychosis: Functional outcome and relapse rate	
13.00 – 14.30	Lunch Break				13.30 – 14.30 h P-01, P-02, P-03, P-04
14.30 – 16.00	S-05 Approaches towards a re-classification of schizophrenia	S-06 Working together: Vocational recovery in early psychosis	S-07 New genetic results from the German Competence Network on Schizophrenia and beyond	S-08 The immune system's impact in pathophysiology and therapy of schizophrenia	
16.00 – 16.30	Coffee Break				
16.30 – 18.00	S-09 Neuroimaging in schizophrenia research	S-10 Addressing stigma – a quality feature for best psychiatric care	W-01 Classification of psychotic disorders: Considerations for DSM-V and ICD-11	O-01 Diagnosis and symptomatology	
18.00 – 19.00	Welcome Reception in the Foyer				

### Abbreviations

S – Symposium

PL – Plenary

O – Oral Presentation

P – Guided Poster Tour

W – Workshop

## OVERVIEW – Tuesday, 22 September 2009

Room	Plenary	Harvard	Stanford	Princeton	Foyer
08.30 – 10.00	<b>S-11</b> Early course and recognition of psychosis	<b>S-12</b> Polypharmacy in schizophrenia – is there a rationale?	<b>S-13</b> Schizophrenia as a disorder of default regeneration: Facts and treatment options	<b>O-02</b> Neuro-psychology I	<b>Registration</b> 08.00 – 18.30
10.00 – 10.30	<b>Coffee Break</b>				
10.30 – 12.00	<b>S-14</b> Current results from the European Prediction of Psychosis Study (EPOS)	<b>S-15</b> European practice guidelines: Survey and implementation	<b>S-16</b> Can a translational approach lead to novel diagnostic and therapeutic perspectives in schizophrenia?	<b>O-03</b> Neuro-psychology II	
12.15 – 13.00	<b>PL-02</b> Early recognition and early intervention				
13.00 – 14.30	<b>Lunch Break</b>				
14.30 – 16.00	<b>S-17</b> Motivational loss and mood symptoms in first episode psychosis	<b>S-18</b> New psychosocial treatment options in schizophrenia	<b>S-19</b> Interventions in people at risk of psychosis: Recent approaches	<b>O-04</b> Neuro-imaging	
16.00 – 16.30	<b>Coffee Break</b>				
16.30 – 18.00	<b>S-20</b> First-episode schizophrenia: Early diagnosis, short- and long-term outcome	<b>S-21</b> Recovery and assertive community treatment in first psychosis	<b>S-22</b> Controversies about anti-psychotics: From bench to bed side	<b>O-05</b> Treatment	
18.15 – 19.45	<b>S-23</b> Establishing the validity of community screening to identify children displaying the antecedents of schizophrenia	<b>S-24</b> Addressing the pathophysiology of hallucinations to tailor rTMS treatment	<b>W-02</b> Assessment of outcome to antipsychotic therapy beyond symptom improvement	<b>O-06</b> Early stages of schizophrenia	

**OVERVIEW – Wednesday, 23 September 2009**

<b>Room</b>	<b>Plenary</b>	<b>Harvard</b>	<b>Stanford</b>	<b>Princeton</b>	<b>Foyer</b>
<b>Time</b>					
08.30 – 10.00	<b>S-25</b> Is neurocognitive dysfunction a core feature of schizophrenia?	<b>S-26</b> Obstacles in the management of schizophrenia patients	<b>S-27</b> Neurobiology of schizophrenia and comorbid cannabis abuse	<b>S-28</b> Phenotypes and the genetics of schizophrenia	<b>Registration</b> 08.00 – 18.00
10.00 – 10.30	<b>Coffee Break</b>				
10.30 – 12.00	<b>S-29</b> Are there any valid neuro-functional and neurostructural endophenotypes for schizophrenia?	<b>W-03</b> Comparative effectiveness of antipsychotics in the treatment of schizophrenia: Guidelines for clinical practice	<b>S-30</b> Positive Symptoms of Psychosis: Psychological models and psychotherapeutic interventions	<b>S-31</b> What can animal models of schizophrenia tell us about basic cognition and risk-related phenotypes?	
12.15 – 13.00	<b>PL-03</b> Psychological treatments in schizophrenia				
13.00 – 14.30	<b>Lunch Break</b>				<b>13.30 – 14.30 h</b> <b>P-08, P-09, P-10, P-11</b>
14.30 – 16.00	<b>S-32</b> Large scale proteomic and gene expression studies on post-mortem brains in schizophrenia: What have we gained?	<b>S-33</b> Cognitive remediation and social functioning in schizophrenia	<b>S-34</b> Prediction of neuroleptic treatment response in schizophrenia	<b>S-35</b> Neurobiological and neuro-cognitive findings in persons at risk for psychosis	
16.00 – 16.30	<b>Coffee Break</b>				
16.30 – 17.00	<b>Closing Ceremony</b>				
17.00 – 18.30		<b>O-07</b> Comorbidity	<b>S-37</b> Learning potential and related concepts in schizophrenia: From neuro-biology to clinical practice	<b>S-38</b> Cycloid psychoses: From clinical concepts to biological foundations	